Prostate Cancer Foundation/X
Dec 30, 2024, 04:50
Improved survival rates for veterans with de novo mHSPC – Prostate Cancer Foundation
Prostate Cancer Foundation shared a post on X:
“VA study shows improved survival rates for veterans with de novo metastatic hormone-sensitive prostate cancer (mHSPC). Combination therapy is now used in 70% of cases.
Dr. Bruce Montgomery, Neeraj Agarwal and Martin Schoen discuss on Urotoday.”
More posts featuring Prostate Cancer Foundation.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 25, 2025, 12:37
Aug 25, 2025, 12:23
Aug 25, 2025, 11:07
Aug 25, 2025, 09:45
Aug 25, 2025, 09:09